By Greg Ryan ( January 31, 2013, 4:56 PM EST) -- The Second Circuit denied a plaintiff's bid for a retrial Wednesday in a bellwether case in multidistrict litigation claiming Merck & Co.'s bone drug Fosamax causes jaw deterioration, ruling a lower court did not err when it discredited expert testimony....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.